The second 21st Century Cures Act includes a provision to force the US Medicare agency to cover breakthrough medical devices for elderly patients, among other mandates.
The US Centers for Medicare and Medicaid has so far resisted lobbying efforts to implement the Medicare Coverage for Innovative Technology (MCIT) rule that would require it to temporarily cover breakthrough devices. But that may be a moot issue if the latest iteration of the 21st Century Cures Act is signed into law.
Reps. Diana DeGette, D-CO, and Fred Upton, R-MI, formally introduced the second version of the 21st Century Cures Act, also known as Cures 2.0, in the US House Energy...
During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.
Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
